161 related articles for article (PubMed ID: 35633498)
1. Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.
Bartalena L; Marcocci C; Tanda ML; Marinò M
J Endocrinol Invest; 2022 Aug; 45(8):1603-1604. PubMed ID: 35633498
[No Abstract] [Full Text] [Related]
2. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?
Bartalena L; Marinò M; Marcocci C; Tanda ML
J Endocrinol Invest; 2022 Jul; 45(7):1455-1457. PubMed ID: 35403994
[No Abstract] [Full Text] [Related]
3. Ototoxicity and Teprotumumab.
Highland J; Gordon S; Reddy D; Patel N
Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
[TBL] [Abstract][Full Text] [Related]
4. Teprotumumab: First Approval.
Markham A
Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
[TBL] [Abstract][Full Text] [Related]
5. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
6. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
Chern A; Dagi Glass LR; Gudis DA
Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?
Piantanida E; Bartalena L
J Endocrinol Invest; 2017 Aug; 40(8):885-887. PubMed ID: 28634704
[No Abstract] [Full Text] [Related]
8. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
9. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.
Hwang CJ; Nichols EE; Chon BH; Perry JD
Eur J Ophthalmol; 2022 May; 32(3):NP46-NP49. PubMed ID: 33525898
[TBL] [Abstract][Full Text] [Related]
10. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
[TBL] [Abstract][Full Text] [Related]
11. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
Genere N; Stan MN
Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
[TBL] [Abstract][Full Text] [Related]
12. Teprotumumab for Active Thyroid Eye Disease. Reply.
Douglas RS; Kahaly GJ
N Engl J Med; 2020 May; 382(20):1959-1960. PubMed ID: 32402172
[No Abstract] [Full Text] [Related]
13. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.
Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD
Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314
[TBL] [Abstract][Full Text] [Related]
14. Teprotumumab for the treatment of thyroid eye disease.
Ju Y; Yang J
Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
[TBL] [Abstract][Full Text] [Related]
15. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
Ali F; Chorsiya A; Anjum V; Ali A
Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
[TBL] [Abstract][Full Text] [Related]
16. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
Slentz DH; Nelson CC; Smith TJ
Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
[TBL] [Abstract][Full Text] [Related]
17. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
[TBL] [Abstract][Full Text] [Related]
18. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
Smith TJ
J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab-Induced Encephalopathy: A Rare Side Effect of a Novel Therapeutic.
Yee MD; McCarthy J; Quinn B; Surani A
WMJ; 2023 May; 122(2):134-137. PubMed ID: 37141481
[TBL] [Abstract][Full Text] [Related]
20. Treatment of moderate-to-severe and active Graves' orbitopathy: a step forward from the OPTIC study.
Tanda ML; Gallo D; Ippolito S; Bartalena L; Piantanida E
J Endocrinol Invest; 2020 Oct; 43(10):1523-1525. PubMed ID: 32306294
[No Abstract] [Full Text] [Related]
[Next] [New Search]
